Get the app
USHealthcare

Xencor Inc (XNCR)

US · Healthcare · Biotechnology

$24.59+3.71%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$51.2M
Revenue YoY
+17.5%
Net profit
$-21.7M
EPS
$-0.29
EPS estimate
$-0.82
Net margin
-42.4%

EPS came in at -0.29 against a street estimate of -0.82 — a beat of 64.6%.

Key statistics

Market cap
$1.81B
Forward P/E
68.0
P/B
3.61
Book value
$6.77
EPS (TTM)
$-2.16
52-week high
$30.61
52-week low
$8.49
50-day MA
$21.80
200-day MA
$15.32
Beta
0.88

Analyst view

Analysts rate Xencor Inc a strong buy (11 buy, 0 hold, 1 sell out of 12) with an average price target of $30.75.

Shareholding

Insiders
1.22%
Institutions
114.66%

Largest institutional holders

FundStake
BlackRock Inc17.53%
PRIMECAP Management Company13.69%
Bvf Inc9.59%
RTW INVESTMENTS, LLC9.12%
RA Capital Management, LLC6.59%
State Street Corp5.85%
Vanguard Portfolio Management, LLC4.71%
Vanguard Capital Management, LLC4.17%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
XENCOR, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $44.7 million in cash and equivalents as of June 30, 2026 (down from $54.1 mil
2026-08-05
Results announced · Q3 2026
XENCOR, INC. – Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $486.4 million as of June 30, 2026 (down from $610.8 million at D
2026-08-05
Results announced · Q3 2026
XENCOR, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Xencor settled a commercial dispute with Alexion Pharma International Operations Limited on July
2026-07-29
Shareholder vote results · Q2 2026
XENCOR, INC. - 2026 ANNUAL SHAREHOLDER MEETING SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 16, 2026 • 63,939,410 shares present
2026-06-18
Quarterly report · Q1 2026
XENCOR, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $14.2 million in cash and equivalents at March 31, 2026, down from $54.1 milli
2026-05-06
Results announced · Q2 2026
XENCOR Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $541.8 million as of March 31, 2026 (down from $610.8 million at December
2026-05-06
Proxy statement · Q2 2026
XENCOR, INC. — 2026 PROXY SUMMARY --- CEO COMPENSATION • Bassil I. Dahiyat (President, CEO, and Director) total compensation for 2025: specific dol
2026-04-27
Annual report FY2025
XENCOR, INC. — FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Fiscal Year: December 31, 2025 • Stock Symbol: XNCR (Nasdaq Global Market)
2026-02-25

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Xencor Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.